TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37278621

Group type: EXPERIMENTAL
Intervention: Virtual reality glasses (360° virtual reality video)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard procedure (control group)
Number of subjects: 44
Study: 37278638

Group type: EXPERIMENTAL
Intervention: Blockade of ATX or LPAR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraplantar injection of cancer exosomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of ATX or blockade of LPAR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parallel in vitro studies
Number of subjects: 0
Study: 37278657

Group type: EXPERIMENTAL
Intervention: Bladder-filling pain positive status (BFP+)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: UCPPS subtype with bladder-filling pain (BFP+)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: UCPPS subtypes
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Pain ratings at baseline and 6 months
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging post-consumption
Number of subjects: 429
Study: 37278662

Group type: EXPERIMENTAL
Intervention: Qualitative rapid analysis approach for intervention design
Number of subjects: 35
Study: 37278682

Group type: EXPERIMENTAL
Intervention: TPV22
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: TPV25
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: TPV22 and TPV25 combined
Number of subjects: 87
Study: 37278684

Group type: EXPERIMENTAL
Intervention: Irrigated needle ablation (INA)
Number of subjects: 111
Study: 37278690

Group type: EXPERIMENTAL
Intervention: E-health (4-month subscription to the online Goalistics Chronic Pain Management Program)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 165
Study: 37278744

Group type: EXPERIMENTAL
Intervention: Medial Closing Distal Femoral Osteotomy (MCDFO)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lateral Opening Distal Femoral Osteotomy (LODFO)
Number of subjects: 22
Study: 37278760

Group type: EXPERIMENTAL
Intervention: Integrating sublingual microcirculatory perfusion variables in the therapy plan
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual routine care
Number of subjects: 141
Study: 37278858

Group type: EXPERIMENTAL
Intervention: Metformin plus low-dose temozolomide (50 mg/m²)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo plus low-dose temozolomide (50 mg/m²)
Number of subjects: 81
Study: 37278879

Group type: EXPERIMENTAL
Intervention: Adavosertib (AZD1775) 175 mg orally twice a day on days 1-3 and 8-10 of a 21-day treatment cycle
Number of subjects: 80
Study: 37278968

Group type: EXPERIMENTAL
Intervention: D-galactose supplementation (1.5 g/kg/day for 6 months)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: D-galactose supplementation
Number of subjects: 12
Study: 37278972

Group type: EXPERIMENTAL
Intervention: GB223 (7, 21, 63, 119, or 140 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: GB223
Number of subjects: 44
Study: 37278999

Group type: EXPERIMENTAL
Intervention: Peer health coaching intervention for 12 months with educational materials, automatic blood pressure monitor, scale, pill organizer, and healthy nutrition tools.
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual care plus educational materials (control group).
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Peer health coaching intervention.
Number of subjects: 264
Study: 37278998

Group type: EXPERIMENTAL
Intervention: Intramedullary Nail (IMN)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Sliding Hip Screw (SHS)
Number of subjects: 850
Study: 37279000

Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-90)
Number of subjects: 6412

Group type: COMPARATOR
Intervention: Clopidogrel-aspirin (300-mg loading dose on day 1 followed by 75 mg/d for days 2-90)
Number of subjects: 6412

Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 6412

Group type: COMPARATOR
Intervention: Clopidogrel-aspirin
Number of subjects: 6412

Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin among poor metabolizers
Number of subjects: 6412

Group type: COMPARATOR
Intervention: Clopidogrel-aspirin among poor metabolizers
Number of subjects: 6412
Study: 37279009

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 0
Study: 37279034

Group type: EXPERIMENTAL
Intervention: New insulin pump
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New glucose sensor
Number of subjects: 0
Study: 37279301

Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg BID for 24 hours, then 50 mg BID for 13 days)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 37279578

Group type: EXPERIMENTAL
Intervention: Cell-based therapy (mesenchymal stem cells)
Number of subjects: 29
Study: 37279602

Group type: EXPERIMENTAL
Intervention: Oral camostat for 7 days
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 37279641

Group type: EXPERIMENTAL
Intervention: MMM CBT treatment (9-13 sessions)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 396
Study: 37279709

Group type: EXPERIMENTAL
Intervention: Caffeine (2.5 mg/kg, twice over 24 h)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 37279780

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pegylated liposomal doxorubicin (PLD) and cyclophosphamide plus trastuzumab/pertuzumab (HP) followed by nab-paclitaxel and HP.
Number of subjects: 96
Study: 37279786

Group type: EXPERIMENTAL
Intervention: Endoscopic resection (ER) defect size ≥ 90% of luminal circumference
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Endoscopic resection (ER) defect size 60%-89% of luminal circumference
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Endoscopic resection (ER) defect size < 60% of luminal circumference
Number of subjects: 916
Study: 37279797

Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg weekly)
Number of subjects: 22
Study: 37279836

Group type: EXPERIMENTAL
Intervention: Degradable Hydrogel for sustained localized delivery of anti-tumor drugs; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct intratumoral injection of a drug; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 37279840

Group type: EXPERIMENTAL
Intervention: Watchman FLX device
Number of subjects: 3000

Group type: COMPARATOR
Intervention: DOACs
Number of subjects: 3000
Study: 37279855

Group type: EXPERIMENTAL
Intervention: Urinary-derived human chorionic gonadotropin/epidermal growth factor (uhCG/EGF; Pregnyl; Organon, Jersey City, NJ) added to standard aGVHD therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard aGVHD therapy (methylprednisolone 48 mg/m2)
Number of subjects: 22
Study: 37279993

Group type: EXPERIMENTAL
Intervention: Nivolumab (NivoMes, NCT02497508) or nivolumab and ipilimumab (INITIATE, NCT03048474)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Detection of two-specific TCR clusters
Number of subjects: 49
Study: 37279999

Group type: EXPERIMENTAL
Intervention: Letermovir, 480 mg, orally daily (with acyclovir)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Valganciclovir, 900 mg, orally daily (adjusted for kidney function)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 601

Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 601
Study: 37280022

Group type: EXPERIMENTAL
Intervention: Bedtime diuretics
Number of subjects: 552

Group type: COMPARATOR
Intervention: Non-diuretics
Number of subjects: 552
Study: 37280026

Group type: EXPERIMENTAL
Intervention: Kidney biopsy
Number of subjects: 300
Study: 37280029

Group type: EXPERIMENTAL
Intervention: Cohort study among PLHIV and healthcare workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of aggregated patient data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of facility implementation of infection prevention and control measures
Number of subjects: 0
Study: 37280081

Group type: EXPERIMENTAL
Intervention: Remimazolam (RMZ group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX group)
Number of subjects: 103
Study: 37280082

Group type: EXPERIMENTAL
Intervention: Pectoserratus and interpectoral plane block combined with general anesthesia (ropivacaine 3.75 mg/mL and clonidine 3.75 µg/mL in 40 mL of 0.9% sodium chloride)
Number of subjects: 164
Study: 37280083

Group type: EXPERIMENTAL
Intervention: 24-hour group (last dose at 07:00 the day prior to surgery)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 36-hour group (last dose at 19:00 2 days prior to surgery)
Number of subjects: 103
Study: 37280116

Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breakthrough cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptomatic COVID-19 breakthrough cases
Number of subjects: 0
Study: 37280238

Group type: EXPERIMENTAL
Intervention: GRT-R910
Number of subjects: 0
Study: 37280275

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP) chemotherapy
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP) chemotherapy combined with immunotherapy
Number of subjects: 519
Study: 37280417

Group type: EXPERIMENTAL
Intervention: HidroQoL questionnaire
Number of subjects: 529
Study: 37280508

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP) ventilation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups (HFNC, nCPAP, and usual care)
Number of subjects: 150
Study: 37280530

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospitalized COVID-19 patients
Number of subjects: 0
Study: 37280551

Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 52
Study: 37280561

Group type: EXPERIMENTAL
Intervention: Meaningful Activities and Recovery (MA&R) intervention
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard mental health care
Number of subjects: 139
Study: 37280584

Group type: EXPERIMENTAL
Intervention: 12-week remote supervised videoconference-based intervention, consisting of 2 weekly 45-min group sessions with progressive resistance exercises
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 130
Study: 37280635

Group type: EXPERIMENTAL
Intervention: Socially deprived category (FDep5)
Number of subjects: 10078

Group type: COMPARATOR
Intervention: Other categories of FDep
Number of subjects: 10078
Study: 37280637

Group type: EXPERIMENTAL
Intervention: Global posture reeducation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Segmental muscle stretching exercises
Number of subjects: 40
Study: 37280638

Group type: EXPERIMENTAL
Intervention: Multi-component intervention package (CombinADO strategy)
Number of subjects: 59
Study: 37280643

Group type: COMPARATOR
Intervention: Delpazolid 0 mg once daily for 16 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Delpazolid 400 mg once daily for 16 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg once daily for 16 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Delpazolid 1200 mg once daily for 16 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg twice daily for 16 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no delpazolid)
Number of subjects: 75
Study: 37280688

Group type: COMPARATOR
Intervention: Lamotrigine (LTG) 300 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lovastatin (LOV) 200 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 37280696

Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE) following classical static cold storage (4 °C) for 1 to 4 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static cold storage (control group)
Number of subjects: 0
Study: 37282500

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37282666

Group type: EXPERIMENTAL
Intervention: Pralsetinib 400-mg once-daily oral
Number of subjects: 68
Study: 37282797

Group type: EXPERIMENTAL
Intervention: Combination therapy (conventional speech therapy and singing intervention)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional speech therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Singing intervention
Number of subjects: 33
Study: 37283558

Group type: EXPERIMENTAL
Intervention: Weaning policy/protocol
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: IWS policy/protocol
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Weaning policy/protocol utilization
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: IWS policy/protocol utilization
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Weaning policy/protocol based on duration of opioid/sedative use
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: IWS policy/protocol for patients on opioids/sedatives ≥ 72 hours
Number of subjects: 1506
Study: 37283627

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 μg/kg, single oral dose)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 37283819

Group type: EXPERIMENTAL
Intervention: rFIXFc prophylaxis
Number of subjects: 92
Study: 37283943

Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 antibodies tested at baseline, 8 weeks, and 16 weeks.
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: IgG titer measurement over time.
Number of subjects: 648
Study: 37283969

Group type: EXPERIMENTAL
Intervention: 0.5 mL (135 μg) candidate vaccine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.0 mL (270 μg) candidate vaccine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Candidate vaccine (both dosages)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 37283972

Group type: EXPERIMENTAL
Intervention: sIPV
Number of subjects: 381
Study: 37283977

Group type: EXPERIMENTAL
Intervention: LLDT-8 0.5 mg daily
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: LLDT-8 1 mg daily
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 37283994

Group type: EXPERIMENTAL
Intervention: Endometriosis symptoms (pelvic pain, dyspareunia, heavy bleeding)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Endometriosis impacts
Number of subjects: 40
Study: 37284020

Group type: EXPERIMENTAL
Intervention: Social alarms
Number of subjects: 278
Study: 37284066

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37284181

Group type: EXPERIMENTAL
Intervention: Auriculotherapy (3 sessions, 1 month apart, using semi-permanent needles)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 90
Study: 37284297

Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance prophylactic cranial irradiation (HA-PCI)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard prophylactic cranial irradiation (PCI)
Number of subjects: 161
Study: 37284327

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham spinal procedure
Number of subjects: 10
Study: 37284613

Group type: EXPERIMENTAL
Intervention: Parathyroid autografts
Number of subjects: 115
Study: 37284759

Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation (TPNS) on
Number of subjects: 48

Group type: COMPARATOR
Intervention: Transvenous phrenic nerve stimulation (TPNS) off
Number of subjects: 48
Study: 37284847

Group type: EXPERIMENTAL
Intervention: NK-1 receptor antagonist (fosaprepitant 150 mg IV or aprepitant 130 mg IV)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo (no NK-1 receptor antagonist)
Number of subjects: 690
Study: 37285038

Group type: EXPERIMENTAL
Intervention: High-precision image-guided cardiac SBRT with 25 Gy delivered to the VT substrate.
Number of subjects: 5
Study: 37285046

Group type: EXPERIMENTAL
Intervention: High-pressure bandage (45-55 mmHg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low-pressure bandage (20-30 mmHg)
Number of subjects: 21
Study: 37285069

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105
Study: 37285075

Group type: EXPERIMENTAL
Intervention: First magnesium tertile
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Third magnesium tertile
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Vitamin D sufficient participants in first magnesium tertile
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Achieved magnesium tertiles at week 4
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Fatigue scores
Number of subjects: 253
Study: 37285081

Group type: EXPERIMENTAL
Intervention: Tirzepatide 2.5-10.0 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tirzepatide 2.5-15.0 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 37285113

Group type: EXPERIMENTAL
Intervention: MOTS-c peptide treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study: 37285133

Group type: EXPERIMENTAL
Intervention: Guided i-CBT
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Self-guided i-CBT
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 1319
Study: 37285195

Group type: EXPERIMENTAL
Intervention: CSM-IBD intervention (8-session program delivered over 8-12 weeks with check-ins with a registered nurse)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 54
Study: 37285278

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily (o.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37285326

Group type: EXPERIMENTAL
Intervention: Lactobacillus coryniformis K8 (3×10^9 CFU) per day
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 255
Study: 37285482

Group type: EXPERIMENTAL
Intervention: Maternal pertussis vaccination
Number of subjects: 0
Study: 37285526

Group type: EXPERIMENTAL
Intervention: Heart transplantation from circulatory-death donor
Number of subjects: 180

Group type: COMPARATOR
Intervention: Heart transplantation from brain-death donor
Number of subjects: 180
Study: 37285718

Group type: EXPERIMENTAL
Intervention: Eribulin monotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Eribulin plus anlotinib
Number of subjects: 80
Study: 37285766

Group type: EXPERIMENTAL
Intervention: High intensity interval-based inspiratory muscle training (H-IMT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (unloaded IMT)
Number of subjects: 34
Study: 37285801

Group type: EXPERIMENTAL
Intervention: Cholecalciferol OTF strips (40,000 IU) administered for 12 weeks
Number of subjects: 20
Study: 37285865

Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide (talazoparib 0.5 mg + enzalutamide 160 mg)
Number of subjects: 805

Group type: COMPARATOR
Intervention: Placebo plus enzalutamide (placebo + enzalutamide 160 mg)
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 805
Study: 37285925

Group type: EXPERIMENTAL
Intervention: Lotilaner ophthalmic solution 0.25%
Number of subjects: 412

Group type: COMPARATOR
Intervention: Vehicle without lotilaner
Number of subjects: 412
Study: 37286048

Group type: EXPERIMENTAL
Intervention: 1 intravenous dose of 24 mg dexamethasone (DX1)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 2 intravenous doses of 24 mg dexamethasone (DX2)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Primary outcome: average peak pain intensity during the 40FPW, TUG, 30CST and SCT.
Number of subjects: 252
Study: 37286131

Group type: EXPERIMENTAL
Intervention: Decision support training for family caregivers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37286215

Group type: EXPERIMENTAL
Intervention: MMR vaccine (M-M-R VaxPro)
Number of subjects: 6540

Group type: COMPARATOR
Intervention: Placebo (solvent only)
Number of subjects: 6540

Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 6540
Study: 37286268

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 170

Group type: COMPARATOR
Intervention: bDMARDs
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Tofacitinib and bDMARDs
Number of subjects: 170
Study: 37286303

Group type: EXPERIMENTAL
Intervention: Tebentafusp plus durvalumab
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Tebentafusp plus tremelimumab
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Tebentafusp plus durvalumab and tremelimumab
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Tebentafusp (alone or in combination)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Tebentafusp with checkpoint inhibitors
Number of subjects: 85
Study: 37286305

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 65
Study: 37286312

Group type: EXPERIMENTAL
Intervention: Intravesical recombinant BCG (rBCG: VPM1002BC) applied weekly for three instillations followed by four cycles of neoadjuvant cisplatin/gemcitabine every 3 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks started together with rBCG and given for four cycles, continued as maintenance therapy after surgery every 3 weeks for 13 cycles.
Number of subjects: 0
Study: 37286317

Group type: EXPERIMENTAL
Intervention: Emergency single-level cerclage with vaginal progesterone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Emergency double-level cerclage with vaginal progesterone
Number of subjects: 78
Study: 37286316

Group type: EXPERIMENTAL
Intervention: Patient-provider communication tool
Number of subjects: 125